|
23 Jan 2020 |
Altimmune Announces Positive Results for ALT-702 in Preclinical Model of Colorectal Cancer
|
|
22 Jan 2020 |
Ra Pharmaceuticals Announces Clearance of IND Application for the HEALEY ALS Platform Trial
|
|
21 Jan 2020 |
Stealth BioTherapeutics Initiates First-in-Human Study of SBT-272
|
|
17 Jan 2020 |
Rybelsus label updated with additional information from the PIONEER 6 CV outcomes trial
|
|
13 Jan 2020 |
Aeglea BioTherapeutics Submits CTA Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)
|
|
13 Jan 2020 |
MIRROR Open-Label Study Topline Data of Methotrexate with KRYSTEXXA (pegloticase injection) Indicates Significant Improvement in Response Rate
|
|
12 Jan 2020 |
Codexis and Nestlé Health Science Sign Development Agreement to Advance Therapeutic Candidate towards Clinical Studies and Extend Strategic Collaboration Agreement
|
|
09 Jan 2020 |
Cybrexa Therapeutics Announces CBX-12 as Lead Development Program
|
|
09 Jan 2020 |
Gemini Therapeutics Enrolls First Patient in Phase 1 Study of GEM103 for Dry Age-related Macular Degeneration
|
|
09 Jan 2020 |
CohBar Discovers Novel Peptide Inhibitors of CXCR4, a Key Regulator of Tumor Growth and Metastasis
|
|
09 Jan 2020 |
Entrada Therapeutics Announces ENTR-501 for the Treatment of Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)
|
|
09 Jan 2020 |
Bicycle Therapeutics and Cancer Research UK to Collaborate on Development of New Bicycle® Immuno-oncology Candidate, BT7401
|
|
08 Jan 2020 |
Bone Biologics Preclinical Study Shows rhNELL-1 Effectively Promotes Bone Formation
|
|
07 Jan 2020 |
Xeris Pharmaceuticals Announces Positive Results from the In-Clinic Stage of a Phase 2 Study of Its Developmental Ready-To-Use (RTU) Glucagon in Patients at Risk of Hypoglycemia During and after Aerobic Exercise
|
|
06 Jan 2020 |
Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Hereditary Hemochromatosis
|
|
30 Dec 2019 |
Jazz Pharmaceuticals Announces First Patient Enrolled in Pivotal Phase 2/3 Study Evaluating JZP-458 for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
|
|
30 Dec 2019 |
Savara Granted Breakthrough Therapy Designation for Molgradex for the Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
|
|
21 Dec 2019 |
ContraFect Announces Initiation of Pivotal Phase 3 DISRUPT Study of Exebacase as a treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis
|
|
21 Dec 2019 |
Aravive Initiates a Phase 2a Clinical Trial of AVB-500 in Patients with Kidney Fibrosis
|
|
21 Dec 2019 |
Stealth BioTherapeutics Provides Update on Phase 3 Trial of Elamipretide in Primary Mitochondrial Myopathy
|
|
20 Dec 2019 |
Chondrial Therapeutics Announces Dosing of First Patients in Phase 1 Clinical Program of CTI-1601 for Treatment of Friedreich’s Ataxia
|
|
20 Dec 2019 |
ContraFect Announces First Gram-negative Product Candidate CF-370, a Direct Lytic Agent Targeting Pseudomonas aeruginosa
|
|
20 Dec 2019 |
Ultragenyx Announces Sale of Future European Royalties on Crysvita® (burosumab) for $320 Million to Royalty Pharma
|
|
20 Dec 2019 |
Rezolute, Inc. Announces Top-line Results from Phase 1 Trial Evaluating AB101 in Patients with Diabetes
|
|
18 Dec 2019 |
DiaMedica Therapeutics Announces First Patient Dosed in REDUX Phase II Clinical Trial of DM199 for the Treatment of Chronic Kidney Disease
|
